| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00303862 Details | 2014-05-21 Interventional | 2 | 10 | Cediranib Carcinoma Carcinoma, Rena… Clear Cell Rena… Recurrent Renal… Stage IV Renal … | - - | |||
| NCT00184067 Details | 2014-05-21 Interventional | 2 | 23 | Monatide (IMS 3… Melanoma | Primary PI left institution - | |||
| NCT01684657 Details | 2014-05-20 Interventional | 3 | - | Asenapine Stuttering | Study transferring to another facility - | |||
| NCT00383565 Details | 2014-05-20 Interventional | 2 | 9 | Romidepsin Lymphoma Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Recurrence Recurrent Adult… Recurrent Mantl… | - - | |||
| NCT02034097 Details | 2014-05-19 Interventional | 2 | 0 | Erlotinib Hydro… Carcinoma, Non-… Lung Neoplasms Cancer | GSK has decided to terminate the Product Development of foretinib and conclude our Development
Agreement with Exelixis - | |||
| NCT01309412 Details | 2014-05-19 Interventional | 1 | 9 | Siltuximab Multiple Myelom… Neoplasms, Plas… | Protocol was stopped due to the safety issue in Global - | |||
| NCT00157248 Details | 2014-05-19 Interventional | 2 | 361 | Dabigatran Atrial Fibrilla… Stroke | - - | |||
| NCT01011816 Details | 2014-05-16 Interventional | 3 | 220 | Fibrin Tissue A… Back Pain Intervertebral … Low Back Pain Chronic Low Bac… Degenerative Di… Internal Disc D… | Stopped prior to last subject's last extended follow-up visit (78 weeks) due to lack of
efficacy at the primary study endpoint (26 weeks) - | |||
| NCT00493428 Details | 2014-05-16 Interventional | 2 | 0 | Baclofen Carcinoma Carcinoma, Hepa… Hepatocellular … | The study have been stoped because the protocol is going to be modify. - | |||
| NCT01166126 Details | 2014-05-15 Interventional | 2 | 4 | MTOR Inhibitors Sirolimus Temsirolimus Melanoma Mucosal Melanom… Recurrent Melan… Stage IV Melano… | - The study was terminated due to overall low accrual and a high rate of screening failures. Accrual goal was 38 participants and only 4 participants were actually treated. | |||
| NCT01129557 Details | 2014-05-15 Interventional | 4 | [1 Refs] | 46 | Aliskiren Valsartan Diabetic Nephro… Glomerulonephri… Glomerulonephri… Glomerulonephri… Glomerulosclero… Kidney Diseases Nephrosclerosis Diabetic Nephro… Focal Segmental… Glomerulopathy … Hypertensive Ne… IgA Nephropathy Proteinuric Kid… | - - | ||
| NCT00879229 Details | 2014-05-15 Interventional | 3 | 40 | Ambrisentan Fibrosis Hypertension Hypertension, P… Idiopathic Pulm… Pulmonary Fibro… Pulmonary Hyper… | - Study GS-US-300-0128 was terminated early with enrollment of 40 of 225 planned subjects. | |||
| NCT00684996 Details | 2014-05-15 Interventional | 1/2 | 5 | Antibodies Antibodies, Mon… Antineoplastic … Bevacizumab Immunoglobulins Carcinoma Carcinoma, Rena… Recurrent Renal… Renal Cell Carc… Stage III Renal… Stage IV Renal … | - - | |||
| NCT00517192 Details | 2014-05-14 Interventional | 3 | 40 | Darunavir Ritonavir Tipranavir HIV Infections | - - | |||
| NCT00447902 2005-005023-33 Details | 2014-05-14 Interventional | 3 | 11 | Ritonavir Tipranavir HIV Infections | - Due to an early termination of the trial no analysis has been performed for primary and secondary endpoints | |||
| NCT00023946 Details | 2014-05-14 Interventional | 2 | 50 | Epothilone B Epothilones Bile Duct Neopl… Carcinoma Carcinoma, Hepa… Cholangiocarcin… Gallbladder Neo… Liver Neoplasms Recurrence Adult Primary C… Adult Primary H… Advanced Adult … Cholangiocarcin… Cholangiocarcin… Localized Extra… Localized Gallb… Localized Resec… Localized Unres… Recurrent Adult… Recurrent Extra… Recurrent Gallb… Unresectable Ex… Unresectable Ga… | - - | |||
| NCT01471197 2011-000732-29 Details | 2014-05-12 Interventional | 2 | 9 | Ipilimumab Pemetrexed Lung Neoplasms Lung Cancer - N… | Administrative reasons At the time of the early termination of this study, most participants only had only one on-study tumor assessment performed. Therefore, the tumor response-related endpoints were too immature to report. | |||
| NCT00293111 Details | 2014-05-12 Interventional | 2 | - | Etodolac Multiple Myelom… Neoplasms, Plas… | - - | |||
| NCT00121420 Details | 2014-05-09 Interventional | 2 | - | Motexafin gadol… Brain Neoplasms Neoplasm Metast… Neoplasms Neoplasms, Seco… | - - | |||
| NCT01981499 Details | 2014-05-08 Interventional | 1 | 31 | Cetirizine Migraine Disord… Migraine | The trial was prematurely terminated on 01April2014 due to safety concerns. - |